Nanobiotix Stock Breaks Support Level and Loses 8.5% Over the Week
The Paris-based biotech company is losing ground this Wednesday in a slightly positive SBF 120, thus moving counter to the broader index trend. The stock broke through its support level downward during trading, in a market context dominated by anticipation of the Federal Reserve's decision on interest rates.
A Support Level Breached During Trading and Moving Averages Weighing Heavily on Short-Term Momentum
Nanobiotix declined 1.66% to €29.66 during trading, after breaching its support level at €30.16 — a level that marked the previous day's close. The stock is now trading below this threshold (last price traded at €29.48), intensifying a movement already underway over the past week, which shows a decline of 8.74%. The technical configuration remains under pressure: the price is below the 20-day moving average at €34.29 (a gap of -13.50%) and the 50-day moving average at €34.05 (a gap of -12.89%), two averages that form a difficult ceiling to overcome in the short term.
Only the 200-day moving average at €28.05 remains below the current price, offering a cushion at approximately 5.7% below the current level. The RSI at 39 is approaching oversold territory without entering it, signaling a loss of selling momentum without a clear rebound in sight at this time. The SBF 120, meanwhile, gained 0.45% during trading, which underscores the stock's underperformance in a market generally oriented upward.
Solid Clinical Data Published on September 14, but Received with Caution by the Market
On September 14, 2026, the complete results of a Phase 1 study on NBTXR3 in non-small cell lung cancer were presented at the IASLC World Conference on Lung Cancer in Seoul. The study, sponsored by MD Anderson Cancer Center, focused on patients requiring re-irradiation — one of the most difficult populations to treat — and showed 79% local-regional control at one year. However, these positive results did not halt the stock decline that began on the day of their publication, with the biotech declining 6% at that time, illustrating a persistent gap between scientific advances and market reaction.
Over one year, the stock maintains a performance of +273%, but over one month, it has lost 8.17%. The next technical configuration to monitor remains the 200-day moving average at €28.05, the last support level derived from moving averages.
